Literature DB >> 16752046

Endogenous overproduction of beta-amyloid induces tau hyperphosphorylation and decreases the solubility of tau in N2a cells.

Y-P Wang1, X-C Wang, Q Tian, Y Yang, Q Zhang, J-Y Zhang, Y-C Zhang, Z-F Wang, Q Wang, H Li, J-Z Wang.   

Abstract

Although neurofibrillary tangles and senile plaques have been identified as the hallmark pathological changes in the brain of Alzheimer's disease (AD), the relationship between them is still not fully understood. In the present study, we have studied the effect of endogenously overproduced amyloid beta (A beta) on tau by using wild type amyloid precursor protein (APP) transfected (N2a/APP695), or Swedish mutant APP plus Delta 9 deleted presenilin-1 co-transfected (N2a/APPswe.Delta 9) and APP vector transfected (N2a/vector) cell lines. We measured the secreted and intracellular A beta, including A beta(1-40) and A beta(1-42), by Sandwich ELISA assay. It was shown that the levels of A beta were increased time-dependently in N2a/APP695 and N2a/APPswe.Delta 9 but not in N2a/vector upon butyric acid (BA) treatment. Compared with N2a/vector cells, tau in N2a/APP695 and N2a/APPswe.Delta 9 cells was not extracted by RIPA buffer, and the SDS-extracted tau protein was hyperphosphorylated at Tau-1 and PHF-1 epitopes upon BA treatment. Obvious accumulation of the hyperphosphorylated tau in N2a/APP695 and N2a/APPswe.Delta 9 cells was observed at 48 h after BA treatment. The total level of the extracted tau was reduced in N2a/APP695 and N2a/APPswe.Delta 9 lines compared with N2a/vector cells by Western blot, and this reduction of total tau was also detected by immunofluorescence staining. No obvious alteration of tau mRNA was observed in both N2a/APP695 and N2a/APPswe.Delta 9 cells compared with N2a/vector. This study provides direct evidence demonstrating that endogenously overproduced A beta not only induces tau hyperphosphorylation but also decreases the level and solubility of tau in N2a cell lines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16752046     DOI: 10.1007/s00702-006-0507-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  41 in total

1.  Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse.

Authors:  M C Irizarry; F Soriano; M McNamara; K J Page; D Schenk; D Games; B T Hyman
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

2.  Alzheimer's amyloid-beta peptide inhibits sodium/calcium exchange measured in rat and human brain plasma membrane vesicles.

Authors:  A Wu; C A Derrico; L Hatem; R A Colvin
Journal:  Neuroscience       Date:  1997-10       Impact factor: 3.590

3.  Modulation of Ca2+ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1-40) is dependent on solubility status.

Authors:  Martin Ramsden; Zaineb Henderson; Hugh A Pearson
Journal:  Brain Res       Date:  2002-11-29       Impact factor: 3.252

4.  Calpain inhibitors reduce depolarization induced loss of tau protein in primary septo-hippocampal cultures.

Authors:  A Kampfl; J S Whitson; X Zhao; R Posmantur; G L Clifton; R L Hayes
Journal:  Neurosci Lett       Date:  1995-07-21       Impact factor: 3.046

5.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

Review 6.  Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy.

Authors:  T Harkany; I Abrahám; C Kónya; C Nyakas; M Zarándi; B Penke; P G Luiten
Journal:  Rev Neurosci       Date:  2000       Impact factor: 4.353

Review 7.  Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.

Authors:  Gunnar K Gouras; Claudia G Almeida; Reisuke H Takahashi
Journal:  Neurobiol Aging       Date:  2005-10       Impact factor: 4.673

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2.

Authors:  Emil Adamec; Panaiyur Mohan; Jean P Vonsattel; Ralph A Nixon
Journal:  Acta Neuropathol       Date:  2002-03-23       Impact factor: 17.088

10.  Implants containing beta-amyloid protein are not neurotoxic to young and old rat brain.

Authors:  J A Clemens; D T Stephenson
Journal:  Neurobiol Aging       Date:  1992 Sep-Oct       Impact factor: 4.673

View more
  5 in total

1.  The Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motif.

Authors:  Bryan Maloney; Debomoy K Lahiri
Journal:  Gene       Date:  2011-06-15       Impact factor: 3.688

Review 2.  Death by a thousand cuts in Alzheimer's disease: hypoxia--the prodrome.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2013-02-12       Impact factor: 3.911

3.  The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.

Authors:  Sheng-Jun Fan; Fang-I Huang; Jing-Ping Liou; Chia-Ron Yang
Journal:  Cell Death Dis       Date:  2018-05-29       Impact factor: 8.469

4.  Sample prep for proteomics of breast cancer: proteomics and gene ontology reveal dramatic differences in protein solubilization preferences of radioimmunoprecipitation assay and urea lysis buffers.

Authors:  Lambert C M Ngoka
Journal:  Proteome Sci       Date:  2008-10-24       Impact factor: 2.480

5.  Phosphoproteomic profiling of selenate-treated Alzheimer's disease model cells.

Authors:  Ping Chen; Lixiang Wang; Yong Wang; Shuiming Li; Liming Shen; Qiong Liu; Jiazuan Ni
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.